2021 World Conference on Lung Cancer (Posters)-FP04. Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907

FP04. Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907

Back to course

Video Transcription

Video Summary

Dr. Natasha Lael presents the results of the Checkmate 907 study, which evaluated the use of nivolumab as a second-line treatment for advanced non-small cell lung cancer. The study enrolled 129 immunotherapy naive patients with either squamous or non-squamous histology. Nivolumab was administered at a flat dose of 480 milligrams every four weeks. The primary endpoint was safety, and the results showed that the dosing schedule was consistent with weight-based dosing. The median survival was 10.6 months, and the overall response rate was 17.1%. The safety profile was similar to previous studies, and the efficacy outcomes were comparable as well. These results support the use of nivolumab in this patient population.

Asset Subtitle

Natasha Leighl

Meta Tag

Speaker Natasha Leighl

Topic Immunotherapy (Phase II/III Trials)

Keywords

Dr. Natasha Lael

Checkmate 907 study

nivolumab

non-small cell lung cancer

immunotherapy naive patients